- Home
- PMVP vs MAIA Comparison
PMVP vs MAIA Comparison
Compare PMVP & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- MAIA
- Stock Information
- Founded
- PMVP 2013
- MAIA 2018
- Country
- PMVP United States
- MAIA United States
- Employees
- PMVP N/A
- MAIA N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- MAIA Health Care
- Exchange
- PMVP Nasdaq
- MAIA Nasdaq
- Market Cap
- PMVP 85.5M
- MAIA 62.4M
- IPO Year
- PMVP 2020
- MAIA 2022
- Fundamental
- Price
- PMVP $1.65
- MAIA $2.82
- Analyst Decision
- PMVP Strong Buy
- MAIA
- Analyst Count
- PMVP 4
- MAIA 0
- Target Price
- PMVP $5.75
- MAIA N/A
- AVG Volume (30 Days)
- PMVP 185.0K
- MAIA 60.0K
- Earning Date
- PMVP 11-07-2024
- MAIA 11-05-2024
- Dividend Yield
- PMVP N/A
- MAIA N/A
- EPS Growth
- PMVP N/A
- MAIA N/A
- EPS
- PMVP N/A
- MAIA N/A
- Revenue
- PMVP N/A
- MAIA N/A
- Revenue This Year
- PMVP N/A
- MAIA N/A
- Revenue Next Year
- PMVP N/A
- MAIA N/A
- P/E Ratio
- PMVP N/A
- MAIA N/A
- Revenue Growth
- PMVP N/A
- MAIA N/A
- 52 Week Low
- PMVP $1.33
- MAIA $0.82
- 52 Week High
- PMVP $3.47
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- PMVP 60.86
- MAIA 50.98
- Support Level
- PMVP $1.63
- MAIA $2.36
- Resistance Level
- PMVP $1.69
- MAIA $2.72
- Average True Range (ATR)
- PMVP 0.07
- MAIA 0.22
- MACD
- PMVP 0.01
- MAIA 0.02
- Stochastic Oscillator
- PMVP 52.65
- MAIA 72.28
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.